Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single Dose Study of Dotinurad (FYU-981) in Healthy Men
NCT02348307Phase 1Completed
- Sponsor
- Fuji Yakuhin
- Start
- Mar 2013
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperuricemia and gout comparing FYU-981 with Placebo (2 arms). Primary endpoints: Maximum plasma concentration at 48 hours, Time to reach the peak plasma concentration at 48 hours and 8 more. Started Mar 2013; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT02348307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348307.